Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA. 
Via Investor's Business Daily
Topics Economy Government
News headline image
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth ↗
AstraZeneca (AZN) is a top-quality stock for long-term investors, showing strong revenue growth, high profitability, and solid cash flow generation. 
Via Chartmill
News headline image
Why AstraZeneca Stock Bumped Higher Today ↗
The company is wasting little time figuring out the particulars of a sweeping capital investment program. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs ↗
Via Stocktwits
News headline image
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
From AstraZeneca
Via Business Wire
News headline image
FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio ↗
AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data. 
Via Benzinga
News headline image
Where Will IonQ Be in 10 Years? ↗
A lot can happen for this quantum computing leader over the next decade. 
Via The Motley Fool
News headline image
Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment ↗
Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics. 
Via Investor's Business Daily
News headline image
IonQ (IONQ) Surges on Strong Revenue Outlook and Insider Confidence Amidst Quantum Computing Race
November 14, 2025 – Quantum computing pioneer IonQ (NYSE: IONQ) recently captured significant market attention, with its stock experiencing a notable 3.6% gain on November 5, 2025, driven by an... 
Via MarketMinute
Topics Intellectual Property
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Why AstraZeneca Stock Was a Winner Today ↗
The company inches closer to bringing a new drug to a very large addressable market. 
Via The Motley Fool
News headline image
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial ↗
AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients. 
Via Benzinga
News headline image
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
3 Reasons to Buy IonQ Stock Like There's No Tomorrow ↗
This quantum computing pioneer has tremendous potential. 
Via The Motley Fool
Topics Artificial Intelligence Fraud
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
From AstraZeneca
Via Business Wire
News headline image
Why AstraZeneca Stock Topped the Market on Thursday ↗
Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter. 
Via The Motley Fool
News headline image
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026. 
Via Benzinga
Topics Government
News headline image
AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable ↗
AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 guidance reaffirmed. 
Via Benzinga
News headline image
AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar ↗
AstraZeneca stock jumped Thursday after the drugmaker reported better-than-expected third-quarter sales and earnings. 
Via Investor's Business Daily
News headline image
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto... 
Via Benzinga
Topics Artificial Intelligence
News headline image
AstraZeneca's 9M and Q3 2025 Financial Results
From AstraZeneca
Via Business Wire
News headline image
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Snowflake And SAP Bridge Enterprise Data Silos In Major AI Integration Push ↗
Snowflake Inc. & SAP SE collaborate to integrate their AI and business data clouds, providing faster access to reliable data and streamlining decision-making. 
Via Benzinga
Topics Artificial Intelligence
News headline image
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.